Results 31 to 40 of about 22,759 (276)
OncoImmunology, 2018 The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor ...
Seandean Lykke Harwood +16 more
doaj +1 more source
Antibody Representation Learning for Drug Discovery [PDF]
arXiv, 2022 Therapeutic antibody development has become an increasingly popular approach for drug development. To date, antibody therapeutics are largely developed using large scale experimental screens of antibody libraries containing hundreds of millions of antibody sequences.
arxiv
ASAP-SML: An Antibody Sequence Analysis Pipeline Using Statistical Testing and Machine Learning [PDF]
, 2020 Antibodies are capable of potently and specifically binding individual antigens and, in some cases, disrupting their functions. The key challenge in generating antibody-based inhibitors is the lack of fundamental information relating sequences of antibodies to their unique properties as inhibitors.
arxiv +1 more source
Use of single-chain antibody derivatives for targeted drug delivery [PDF]
, 2016 Single-chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules that can be used for selective drug delivery.
Ahmadzadeh, V. +5 more
core +1 more source
mAbs, 2020 The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide ...
Feng Wang +17 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity [PDF]
, 2020 Antibodies recognizing complexes of the chemokine platelet factor 4 (PF4-CXCL4) and polyanions (P) opsonize PF4-coated bacteria hereby mediating bacterial host defense. A subset of these antibodies may activate platelets after binding to PF4-heparin complexes, causing the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT).
arxiv +1 more source
In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
Molecular Therapy: Methods & Clinical Development, 2017 Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse +6 more
doaj +1 more source
Improving antibody language models with native pairing [PDF]
arXiv, 2023 Current antibody language models are limited by their use of unpaired antibody sequence data and the biases in publicly available antibody sequence datasets, which are skewed toward antibodies against a relatively small number of pathogens. A recently published dataset (by Jaffe, et al) of approximately 1.6 x 10^6 natively paired human antibody ...
arxiv
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]
, 2014 Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core +2 more sources